Clinical trials: Sirolimus
Cutaneous T-Cell Lymphoma
Everolimus in Treating Cutaneous T-cell Lymphoma
CTCL is a rare form of lymphoma of the skin. While early stages are usually confined to the skin, later stages may spread to blood, lymph nodes and other organs. At this point, patients usually require systemic chemo.
- Trial name
- CTCL (NCT01637090)
- Testing
- Everolimus
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Adam Lerner
Prostate Cancer Recurrent, Solid Tumor, Adult
COAST Therapy in Advanced Solid Tumors and Prostate Cancer
The purpose of this Phase I/II study is to determine the safety and effectiveness of up to 5 study drugs used together for the treatment of solid tumor cancers.
- Trial name
- COAST (NCT05036226)
- Testing
- Hydroxychloroquine, Metformin, Sirolimus, Hydroxychloroquine, Metformin, Sirolimus, Dasatanib, Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Medical University of South Carolina
Communicating Hydrocephalus, Cerebral Intraventricular Hemorrhage
The Safety and Efficacy of Rapamycin on Communicating Hydrocephalus Secondary to Intraventricular Hemorrhage
This prospective, multicenter, open-label clinical trial is designed to evaluate the safety and efficacy of rapamycin in the treatment of communicating hydrocephalus secondary to intraventricular hemorrhage.
- Conditions
- Communicating Hydrocephalus, Cerebral Intraventricular Hemorrhage, Secondary Normal Pressure Hydrocephalus, Post Hemorrhagic Hydrocephalus
- Trial name
- Saturn (NCT06563817)
- Testing
- Rapamycin
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Beijing Tiantan Hospital
Peripheral Artery Disease, Atherosclerosis
SirolimUs CoaTed Balloon for The TrEatment of Below The Knee Arterial Disease
This study aims to conduct a randomized, double blind, randomised controlled multicentre trial of sirolimus drug coated balloon versus standard percutaneous transluminal angioplasty for the treatment of below the knee arterial…
- Conditions
- Peripheral Artery Disease, Atherosclerosis, Arterial Disease of Legs
- Trial name
- FUTURE-BTK (NCT04511247)
- Testing
- MagicTouch PTA Sirolimus drug coated balloon, POBA balloon
- Where
- 20 sites in Singapore, Taiwan and 1 more
- Volunteers
- 219 people
- Sponsor
- Concept Medical Inc.
Coronary Artery Disease, Coronary Atherosclerosis
Everolimus Stent in Patients With Coronary Artery Disease (CAD)
Aim of the study is to compare the everolimus eluting stent and sirolimus eluting stent in all comers PCI eligible patients
- Trial name
- RACES (NCT01182649)
- Testing
- coronary stent, stent
- Where
- Italy
- Volunteers
- 600 people
- Sponsor
- San Giuseppe Moscati Hospital
Tumors
Study of Combination of Sirolimus and Sutent in Patients With Advanced Solid Tumors Non-Curable With Standard Therapy
There are two drugs involved in this study. Sunitinib (Sutent(R)) is approved by the Food and Drug Administration (FDA) for the treatment of advanced renal cell (kidney) cancer and gastrointestinal stromal tumors.
- Trial name
- NCT00402415
- Testing
- Sunitinib malate, Rapamycin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Yale University
Graft Versus Host Disease
In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus
In this study the investigators are proposing to treat patients with steroid-refractory Graft-versus-host Disease (GVHD) stabilization using IL-2 and azacitidine
- Trial name
- T-REG (NCT01453140)
- Testing
- Cyclophosphamide and Sirolimus, Low dose IL-2 with Cytoxan + Sirolimus, Low dose IL-2, low dose Vidaza, cyclophosphamide & Sirolimus
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Hackensack Meridian Health
Chronic Myeloid Leukemia
RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.
Patients participating in this study will have a diagnosis of Chronic Myeloid Leukemia. This study will evaluate whether the addition of an investigational drug called RAD001 given together with Imatinib will better target…
- Trial name
- NCT01188889
- Testing
- RAD001, Imatinib
- Where
- United States
- Sponsor
- University of Michigan Rogel Cancer Center
SOLID TUMOR
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus
Preclinical studies and clinical observations have shown the Phosphoinositide 3-kinase (PI3K) /Protein kinase B (AKT) /mammalian (mechanistic) target of Rapamycin (known as the 'mTOR-pathway') signaling to be deregulated in…
- Trial name
- NCT02441543
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- Istituto Clinico Humanitas
Canities, Grey Hair
Clinical Study of mTOR Inhibitor as a Treatment for Grey Hair (Canities)
Clinical Study to Assess the Safety and Efficacy of CS-002 (mTOR inhibitor) as a treatment for Canities (Grey Hair)
- Trial name
- NCT07166354
- Testing
- CS-002
- Volunteers
- 100 people
- Sponsor
- Applied Biology, Inc.
Dilated Cardiomyopathy, Kaposi's Sarcoma-Associated Herpesvirus Infection
The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus
Evaluating the efficacy of sirolimus (compared to standard therapy alone) in the treatment of dilated cardiomyopathy infected with Kaposi Sarcoma-associated virus -- a multicenter randomized controlled study.
- Trial name
- SDCMK (NCT06236022)
- Testing
- Sirolimus
- Where
- China
- Volunteers
- 276 people
- Sponsor
- Tongji Hospital
Chronic Rejection of Cardiac Transplant
Everolimus and Low Dose CNI Compared With MMF and Full CNI Dose in Heart Transplanted Patients: One Year Follow up
The different mechanisms of action of Everolimus and cyclosporine suppress immune function in synergistic manner. Thus it is postulated that the use of Everolimus in combination with cyclosporine permits a significant…
- Trial name
- CRAD001AILO2 (NCT00596557)
- Testing
- everolimus
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Rabin Medical Center
Carcinoma, Renal Cell
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
This is for subjects with metastatic Renal Cell Cancer (RCC). There are four Food and Drug Administration (FDA) approved drugs for first-line therapy of Renal Cell Cancer (RCC) and two for second-line therapy.
- Trial name
- NCT02560012
- Testing
- Sunitinib, Temsirolimus, Sorafenib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- The University of Texas Health Science Center, Houston
Stable Angina, Heart Failure
Plasmonic Nanophotothermal Therapy of Atherosclerosis
The investigators hypothesize that the nanoburning is a very challenging technique to demolish and reverse the plaque especially in combination with stem cell technologies promising the functional restoration of the vessel wall.
- Conditions
- Stable Angina, Heart Failure, Atherosclerosis, Multivessel Coronary Artery Disease
- Trial name
- NANOM-FIM (NCT01270139)
- Testing
- Transplantation of nanoparticles, Transplantation of iron-bearing nanoparticles, Stenting
- Where
- 4 sites in Netherlands, Russia
- Volunteers
- 180 people
- Sponsor
- Ural State Medical University
Adult Acute Lymphoblastic Leukemia, Adult Acute Myeloid Leukemia
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
This phase II trial studies how well sirolimus, cyclosporine and mycophenolate mofetil works in preventing graft-vs-host disease (GVHD) in patients with blood cancer undergoing donor peripheral blood stem cell (PBSC) transplant.
- Conditions
- Adult Acute Lymphoblastic Leukemia, Adult Acute Myeloid Leukemia, Adult Diffuse Large B-Cell Lymphoma, Adult Myelodysplastic Syndrome
- Trial name
- NCT01251575
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate
- Where
- 5 sites in United States, Denmark
- Volunteers
- 77 people
- Sponsor
- Fred Hutchinson Cancer Center
Advanced Malignant Neoplasm, Cervical Squamous Cell Carcinoma
Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations
This pilot trial studies how well nanoparticle albumin-bound rapamycin works in treating patients with cancer that as has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced…
- Conditions
- Advanced Malignant Neoplasm, Cervical Squamous Cell Carcinoma, Endometrial Carcinoma, Malignant Uterine Neoplasm
- Trial name
- NCT02646319
- Testing
- Laboratory Biomarker Analysis, Nanoparticle Albumin-Bound Rapamycin, Quality-of-Life Assessment
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Mayo Clinic
Desmoid Tumor
A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis
Desmoid-type fibromatosis (or desmoid tumor) represents an intermediate grade neoplasm with a striking predilection for locally invasive growth and recurrence following resection. It occurs in children as well as young adults.
- Trial name
- NCT01265030
- Testing
- Sirolimus
- Where
- 8 sites in United States
- Volunteers
- 9 people
- Sponsor
- MaineHealth
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma
This phase I/II trial studies the side effects and best dose of temsirolimus when given together with perifosine and to see how well it works in treating patients with recurrent or progressive malignant glioma.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Diffuse Astrocytoma, Adult Giant Cell Glioblastoma
- Trial name
- NCT01051557
- Testing
- Laboratory Biomarker Analysis, Perifosine, Temsirolimus
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Rejection Heart Transplant, Immunosuppression
Improving Immunosuppressive Therapy in Heart Transplantation
Cardiac allograft rejection (CAR) occurs in 30% to 40% of transplant recipients within the first year post-transplant, and carries an increased risk of both acute graft failure and reduced graft longevity.
- Trial name
- NCT03932539
- Where
- 4 sites in Italy
- Volunteers
- 25 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Peripheral Arterial Disease
Post-market Registry Study on the Safety and Efficacy of ZENFLEX Pro™ Peripheral Drug-eluting Stent System for Femoropopliteal Artery Lesions
This is a prospective, multi-center, single-arm post-market study evaluating the safety and effectiveness of the ZENFLEX Pro™ Drug-eluting Stent in treating femoropopliteal artery stenosis or occlusion.
- Trial name
- NCT07122167
- Testing
- Peripheral Drug-eluting Stent System
- Where
- Poland
- Volunteers
- 153 people
- Sponsor
- MDCECRO LLC